Incyte, Syndax Receive FDA Approval for Niktimvo to Treat Chronic Graft-Versus-Host Disease
Incyte (INCY) and Syndax Pharmaceuticals (SNDX) said Wednesday that the US Food and Drug Administration has approved Niktimvo as a treatment for certain patients with chronic graft-versus-host disease who weigh at least 40 kg.
The company said the drug will be available in two vial sizes -- 9 mg and 22 mg -- and is expected to be available for order in the US starting in early February.
Health care providers can order Niktimvo through a network of specialty distributors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available